Atomo Diagnostics Ltd
ASX:AT1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Atomo Diagnostics Ltd
Revenue
Atomo Diagnostics Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Atomo Diagnostics Ltd
ASX:AT1
|
Revenue
AU$3.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Revenue
AU$118.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Cochlear Ltd
ASX:COH
|
Revenue
AU$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Revenue
AU$697.4k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
37%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Revenue
AU$92.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Revenue
AU$5.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
Atomo Diagnostics Ltd
Glance View
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-04-16. The firm is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. The company also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. The company is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
See Also
What is Atomo Diagnostics Ltd's Revenue?
Revenue
3.9m
AUD
Based on the financial report for Dec 31, 2025, Atomo Diagnostics Ltd's Revenue amounts to 3.9m AUD.
What is Atomo Diagnostics Ltd's Revenue growth rate?
Revenue CAGR 5Y
-15%
Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for Atomo Diagnostics Ltd have been -22% over the past three years , -15% over the past five years .
